News/ News/ R&D Biogen teams up with gene-editing startup Scribe on ALS programme Phil Taylor amyotrophic lateral sclerosis, Biogen, central nervous system, CRISPR/Cas9, licensing, neurodegenerative disease, Scribe Therapeutics 0 Comment Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 Share X Biogen teams up with gene-editing startup Scribe on ALS programme https://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/